Terence P. Gade, MD, PhD, describes research at the Penn Center for Precision Medicine aimed at adding to the drug armamentarium for liver cancer, which currently stands at 10 medications. Focusing on the sensitivity of each patients’ cancer as defined by genetic profiling, the study hopes to discover new agents to combat liver cancer from among the 1700 drugs now approved by the Food and Drug Administration. Dr. Gade is an Assistant Professor in the Departments of Radiology and Cancer Biology at Penn Medicine.
Related Links:
Management of Hepatocellular Carcinoma
Dr Gade’s Profile
Published
February 13, 2018
Created by
BROADCASTMED